Study in Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of GT20029
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose Escalation Study in Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of GT20029 Following Topical Single and Multiple Ascending Dose Administration
In the register
The register attaches this trial to GT20029 (Kintor Pharmaceutical), currently at “Phase 2” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Completed
- Declared phase
- Phase 1
- Sponsor
- Suzhou Kintor Pharmaceutical Inc,
- Participants (registry)
- 123
- Start
- February 2022
- Primary completion
- October 2022
- Study completion
- April 2023
- Last registry update
- August 2023
- Countries
- United States
Conditions studied: Androgenetic Alopecia, Acne Vulgaris
Interventions: GT20029 Gel, GT20029 Gel Placebo
Other trials of GT20029
To Evaluate the Efficacy and Safety of GT20029 Solution in the Treatment of Androgenetic Alopecia (AGA) in Chinese Adult Males
To Evaluate the Safety, Tolerability and PK of GT20029 Gel and Solution in Healthy Subjects
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.